Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping

Tachycardia, Ventricular Clinical Trial

Official title:

Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05086510
• Other study ID #: FMASUMD83/2021
• Status: Completed
• Phase: N/A
• Start date: October 28, 2021
• Est. completion date: June 26, 2023

Study information

• Verified date: July 2023
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims at comparing the recurrence rates of ventricular tachycardia ablated after being mapped by 2 different techniques.

Description:

The study participants are patients presented with recurrent ventricular tachycardia.

They will be divided into 2 groups in terms of mapping. The first group will use mapping during sinus rhythm to identify late potentials that may be incriminated in the tachycardia circuit.

The other group will undergo mapping during right ventricular extrastimulus pacing to unmask hidden potentials. The identified potentials will be ablated in both groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 26, 2023
• Est. primary completion date: June 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• • Patients with structural heart disease; previous myocardial infarction, left ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance or electroanatomic map.

• Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic drug treatment or requiring implantable cardioverter defibrillator therapies.

Exclusion Criteria:

• • Patients with ventricular arrhythmias attributed to reversible causes.

Related Conditions & MeSH terms

• Tachycardia
• Tachycardia, Ventricular

Intervention

Procedure:
• Radiofrequency ablation
Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.

Locations

Country	Name	City	State
Egypt	AinShams university hospitals	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Recurrence of Ventricular Tachycardia	Recurrence of ventricular tachycardia implies receiving at least one appropriate implantable cardioverter defibrillator therapy or hospital admission due to symptomatic ventricular tachycardia.	12 months
Secondary	Number of Participants Who Experience Cardiac Death	This is defined as unexpected death where a cardiac cause is the most probable etiology	12 months
Secondary	Number of Participants Who Die From Any Cause (All-cause Mortality)	This includes death from any cause	12 months